Study on CTP Evaluation of Pathological Parameters of Lung Cancer and the Clinical Efficacy Before and After Radiotherapy and Chemotherapy

doi:10.7517/issn.1674-0475.200310

Abstract

Abstract: To investigate the value of CT perfusion (CTP) in evaluating the pathological parameters of lung cancer and the clinical efficacy before and after radiotherapy and chemotherapy.152 Patients with lung cancer treated with radiation and chemotherapy were chosen as the research object. Different CTP parameters, such as blood flow (BF), blood volume (BV), time to peak (TTP), permeability surface (PS) between the patients with different tumor type, tumor size, radiation and chemotherapy before and after treatment were recorded. Our research found that BF, BV, TTP and PS values were the highest in SCLC, followed by adenocarcinoma and squamous cell carcinoma (P<0.05).The values of BF, BV, TTP and PS in the groups with a volume 40 cm³ before radiotherapy and chemotherapy and without remission were higher than those in the groups with a volume<40 cm³, after radiotherapy and chemotherapy and in the remission group (P<0.05).Thus, CTP parameters were associated with the pathological type and tumor size of lung cancer, and the values of CTP parameters of patients after radiotherapy and chemotherapy and patients in remission are decreased.

Key words: CT perfusion, lung cancer, pathological parameters, clinical curative effects

ZHOU Jie, HU Chunfeng. Study on CTP Evaluation of Pathological Parameters of Lung Cancer and the Clinical Efficacy Before and After Radiotherapy and Chemotherapy[J]. Imaging Science and Photochemistry, 2020, 38(5): 822-827.

References

[1] Wozniak A J, Schwartz A G. Risk of second lung cancer in patients with previously treated lung cancer:analysis of surveillance, epidemiology, and end results data[J]. Journal of Thoracic Oncology, 2018, 13(6):106-107.
[2] Bakan S, Kandemirli S G, Dikici A S, et al. Evaluation of anterior mediastinal solid tumors by CT perfusion:a preliminary study[J]. Diagnostic and Interventional Radiology, 2017, 23(1):10.
[3] 李知书, 马兵, 陈绍平, 等. 螺旋CT及能谱CT与PET-CT扫描诊断肺癌的临床价值比较[J]. 西部医学, 2017, 29(11):1532-1536.
[4] Venkat B, Sharma S, Sharma D, et al. CT perfusion in non-small cell lung cancers for assessing treatment response, monitoring treatment and predicting prognosis[J]. European Radiology, 2018, 49(2):145.
[5] 董瑞彤, 董越, 罗娅红,等. 宫颈鳞癌容积CT灌注参数的测量稳定性和影响因素[J]. 中国医学影像学杂志, 2018, 26(6):11-15.
[6] Jamal-Hanjani M, Wilson G A, Mcgranahan N, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer[J]. New England Journal Medicine, 2017, 376(22):2109-2121.
[7] 赵莹, 刘爱连. 肾上腺肿瘤的CT新技术应用进展[J]. 中国临床医学影像杂志, 2017, 28(11):829-832.
[8] 梁长华, 梁盼, 刘甲,等. 原发性肝癌320排容积CT全肿瘤灌注参数值与微血管密度及其与病理分级的相关性研究[J]. 临床放射学杂志, 2017, 36(4):517-522.
[9] 代光政, 田翠丽, 刘澜涛,等. 不同病理类型肺癌放化疗前后CT灌注参数变化研究[J]. 临床肺科杂志, 2017, 22(11):2081-2084.
[10] Zhang R, Feng L, Dong Z, et al. Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy[J]. Biomaterials, 2018, 162:123-131.
[11] Gao L, Yang Q, Yabin H U, et al. Assessment of bronchial and pulmonary blood supply in lung adenocarcinoma and squamous cell carcinoma using dual-input perfusion CT[J]. China Journal Medical Image Technology, 2017, 33(3):419-422.
[12] Chu L L, Knebel R J, Shay A D, et al. CT perfusion imaging of lung cancer:benefit of motion correction for blood flow estimates[J]. European Radiology, 2018, 28(1):1-7.
[13] 王广丽, 崔丁也, 邓凯, 等. 非小细胞肺癌VEGF表达与CT能谱成像相关性的初步研究[J]. 临床放射学杂志, 2017, 36(8):1111-1114.
[14] Frezzetti D, Gallo M, Maiello M R, et al. VEGF as a potential target in lung cancer[J]. Expert Opinion on Therapeutic Targets, 2017, 21(10):1.
[15] 张士放, 文艳梅, 陈红,等. 靶向抗血管生成治疗非小细胞肺癌的研究进展[J]. 山东医药, 2017, 57(14):107-110.
[16] Malavasi S, Barone D, Gavelli G, et al. Multislice analysis of blood flow values in CT perfusion studies of lung cancer[J]. Biomed Research International, 2017, 2017:1-11.